ERBB2 and breast carcinoma: In agreement with previous findings that mollugin suppressed NF-κB activation in HER2-overexpressing SK-BR-3 breast cancer cells [17], our results indicate that mollugin significantly inhibited NF-κB activation by reducing the level of phospho-IκBα, leading to blockage of the IκBα pathway in NF-κB activation in OSCCs.